Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

ABSTRACT: INTRODUCTION: To assess the effect of canakinumab, a fully human anti-interleukin-1β antibody, on symptoms and health-related quality of life (HRQoL) in patients with cryopyrin-associated periodic syndrome (CAPS). METHODS: In this 48-week, phase 3 study, patients with CAPS received canakin...

Descripción completa

Detalles Bibliográficos
Autores principales: Koné-Paut, Isabelle, Lachmann, Helen J, Kuemmerle-Deschner, Jasmin B, Hachulla, Eric, Leslie, Kieron S, Mouy, Richard, Ferreira, Alberto, Lheritier, Karine, Patel, Neha, Preiss, Ralph, Hawkins, Philip N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334655/
https://www.ncbi.nlm.nih.gov/pubmed/22152723
http://dx.doi.org/10.1186/ar3535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334655/
https://www.ncbi.nlm.nih.gov/pubmed/22152723
http://dx.doi.org/10.1186/ar3535

Ejemplares similares